| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
N/A |
| Shares
Out: |
61,150,000 |
| Market
Cap: |
6.68(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$113.49 - $145.93 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Jazz Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing medicines for patients with serious diseases with limited or no options. Co.'s primary marketed products are: Xyrem® (sodium oxybate) oral solution, for the treatment of both cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Xywav™ (calcium, magnesium, potassium, and sodium oxybates) oral solution, for the treatment of cataplexy or EDS in narcolepsy patients seven years of age and older; and Sunosi® (solriamfetol), to improve wakefulness in adult patients with EDS associated with narcolepsy or obstructive sleep apnea.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
12,000 |
12,000 |
12,000 |
12,000 |
| Total Buy Value |
$1,435,800 |
$1,435,800 |
$1,435,800 |
$1,435,800 |
| Total People Bought |
1 |
1 |
1 |
1 |
| Total Buy Transactions |
1 |
1 |
1 |
1 |
| Total Shares Sold |
8,704 |
9,538 |
26,327 |
202,744 |
| Total Sell Value |
$986,699 |
$1,086,171 |
$3,399,099 |
$29,455,215 |
| Total People Sold |
2 |
4 |
12 |
19 |
| Total Sell Transactions |
3 |
5 |
21 |
74 |
| End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Cozadd Bruce C |
Chairman & CEO |
• • – |
2021-02-03 |
4 |
AS |
$160.00 |
$40,000 |
D/D |
(250) |
318,032 |
|
- |
|
| Cozadd Bruce C |
Chairman & CEO |
• • – |
2021-02-01 |
4 |
AS |
$156.15 |
$195,188 |
D/D |
(1,250) |
318,282 |
|
- |
|
| Cozadd Bruce C |
Chairman & CEO |
• • – |
2021-01-04 |
4 |
AS |
$162.01 |
$1,287,980 |
D/D |
(7,950) |
319,532 |
|
- |
|
| Swisher Daniel N Jr |
President and COO |
• – – |
2021-01-04 |
4 |
D |
$160.40 |
$257,763 |
D/D |
(1,607) |
41,984 |
|
- |
|
| Carr Patricia |
VP, Finance & PAO |
• – – |
2020-12-04 |
4 |
S |
$152.55 |
$9,458 |
D/D |
(62) |
6,200 |
|
- |
|
| Cozadd Bruce C |
Chairman & CEO |
• • – |
2020-12-03 |
4 |
AS |
$150.00 |
$37,500 |
D/D |
(250) |
327,482 |
|
- |
|
| Cozadd Bruce C |
Chairman & CEO |
• • – |
2020-12-01 |
4 |
AS |
$140.58 |
$140,580 |
D/D |
(1,000) |
327,732 |
|
- |
|
| Enright Patrick G |
Director |
– • – |
2020-11-12 |
4 |
AS |
$145.81 |
$1,456,738 |
D/D |
(9,929) |
20,368 |
|
- |
|
| Larkin Finbar |
SVP, Technical Operations |
• – – |
2020-11-06 |
4 |
S |
$151.93 |
$29,930 |
D/D |
(197) |
13,964 |
|
- |
|
| Okeefe Kenneth W |
Director |
– • – |
2020-11-05 |
4 |
AS |
$152.57 |
$1,703,421 |
D/D |
(11,000) |
18,667 |
|
- |
|
| Sohn Catherine A. |
Director |
– • – |
2020-11-04 |
4 |
S |
$152.00 |
$1,918,000 |
D/D |
(12,500) |
10,622 |
|
- |
|
| Sohn Catherine A. |
Director |
– • – |
2020-11-04 |
4 |
OE |
$46.83 |
$742,560 |
D/D |
12,500 |
18,622 |
|
- |
|
| Berns Paul L |
Director |
– • – |
2020-11-04 |
4 |
AS |
$147.44 |
$705,604 |
D/D |
(4,691) |
9,740 |
|
- |
|
| Cozadd Bruce C |
Chairman & CEO |
• • – |
2020-11-03 |
4 |
AS |
$154.00 |
$385,000 |
D/D |
(2,500) |
328,680 |
|
- |
|
| Cozadd Bruce C |
Chairman & CEO |
• • – |
2020-11-02 |
4 |
AS |
$145.13 |
$145,130 |
D/D |
(1,000) |
331,180 |
|
- |
|
| Okeefe Kenneth W |
Director |
– • – |
2020-11-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
22,249 |
29,667 |
|
- |
|
| Enright Patrick G |
Director |
– • – |
2020-11-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,929 |
30,297 |
|
- |
|
| Berns Paul L |
Director |
– • – |
2020-11-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,691 |
14,431 |
|
- |
|
| Cozadd Bruce C |
Chairman & CEO |
• • – |
2020-10-01 |
4 |
AS |
$141.94 |
$638,730 |
D/D |
(4,500) |
332,180 |
|
- |
|
| Larkin Finbar |
SVP, Technical Operations |
• – – |
2020-09-09 |
4 |
S |
$138.53 |
$8,727 |
D/D |
(63) |
14,161 |
|
- |
|
| Cozadd Bruce C |
Chairman & CEO |
• • – |
2020-09-01 |
4 |
AS |
$134.90 |
$67,450 |
D/D |
(500) |
336,680 |
|
- |
|
| Cozadd Bruce C |
Chairman & CEO |
• • – |
2020-08-27 |
4 |
AS |
$130.00 |
$390,000 |
D/D |
(3,000) |
337,180 |
|
- |
|
| Carr Patricia |
VP, Finance & PAO |
• – – |
2020-08-12 |
4 |
AS |
$123.80 |
$17,580 |
D/D |
(142) |
6,200 |
|
- |
|
| Carr Patricia |
VP, Finance & PAO |
• – – |
2020-08-07 |
4 |
S |
$125.87 |
$19,887 |
D/D |
(158) |
6,342 |
|
- |
|
| Sohn Catherine A. |
Director |
– • – |
2020-08-07 |
4 |
S |
$125.87 |
$117,186 |
D/D |
(931) |
10,622 |
|
- |
|
881 Records found
|
|
Page 12 of 36 |
|
|
0.37 (0.34%) 
